Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT05919563
Active, not recruiting Observational

LTFU Study of Subjects Who Received GRNOPC1

NCT05919563 · tracked via the Priya Life Science USA tracker
Sponsor
Lineage Cell Therapeutics, Inc
Phase
Observational
Started
2011-10-06
Last updated
2024-08-21

Condition(s) studied

Spinal Cord Injuries

Investigational drug(s) / intervention(s)

Magnetic Resonance Imaging (MRI)

Magnetic Resonance Imaging (MRI): Observational study; annual MRI for first 5 years only to monitor changes in the injection site

Study summary

This is a LTFU study for thoracic SCI subjects that were administered GRNOPC1 cells in the main study CP35A007.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Subjects who received administration of GRNOPC1 under clinical study protocol CP35A007. Exclusion Criteria: * There are no exclusion criteria for this LTFU study.

Primary outcome measure(s)

  • Incidence and severity of adverse events (AEs) — Up to 15 years after GRNOPC1 injection
    Information will be collected on all adverse events through Year 5 and on late-occurring adverse events (Years 6-15) related to any changes in neurological condition, a fever of unknown etiology, and the development of neoplasias and/or neurological disorders.

Trial sites (3)

FacilityCityRegionStatus
Stanford University Palo Alto California
Shepherd Center Atlanta Georgia
Northwestern Medical Group Evanston Illinois

More Lineage Cell Therapeutics, Inc. trials in the USA

LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1 Active, not recruiting
A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury Recruiting

Other trials for the same condition

Telerehabilitation Early After CNS Injury Active, not recruiting
LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1 Active, not recruiting
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury Recruiting
ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury Recruiting
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05919563 on ClinicalTrials.gov ↗ ← All trials in the USA